Ducreux, Michel
Bennouna, Jaafar
Adenis, Antoine
Conroy, Thierry
Lièvre, Astrid
Portales, Fabienne
Jeanes, Julie
Li, Li
Romano, Alfredo
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
https://doi.org/10.1007/s00280-016-3193-5
Funding for this research was provided by:
Celgene
Article History
Received: 7 October 2016
Accepted: 4 November 2016
First Online: 19 November 2016
Compliance with ethical standards
:
: MD, receipt of grants/research supports: Roche, Chugai, Pfizer; receipt of honoraria or consultation fees: Roche, Celgene, Merck Serono, Amgen, Novartis, Sanofi, Pfizer; JB, receipt of honoraria or consultation fees: Roche, Boehringer Ingelheim, AstraZeneca; AA, nothing to disclose; TC, nothing to disclose; AL, receipt of grants/research supports: Merck Serono; receipt of honoraria or consultation fees: Merck Serono, Roche, Amgen, Sanofi, Lily; FP, nothing to disclose; JJ, LL, AR, employment or leadership and stock ownership: Celgene.
: All relevant ethical approvals from institutional review board/independent ethics committee have been obtained prior to study commencement.
: Informed consent was obtained from all patients prior to study entry.